Special Issue "Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination"
Deadline for manuscript submissions: 20 August 2024 | Viewed by 12006
2. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H3C 3J7, Canada
Interests: HIV-1; intestine mucosa; T lymphocytes; SARS-CoV-2; vaccine; immune responses
The COVID-19 pandemic caused a race for the elaboration of an effective vaccine against SARS-CoV-2. Currently, four vaccines are approved in many countries (Pfizer/BioNtech BNT162b2, Moderna mRNA-1273, Janssen Ad26.COV2S, and Novavax adjuvant). They are based on different technologies, such as mRNA, recombinant replication-incompetent adenovirus, and protein subunit.
There are still limitations in the understanding of the protective components of the immune responses elicited by this vaccine. Such protection is mediated through a complex interplay between innate, humoral, and cell-mediated immunity. Several reports showed that administration of anti-SARS-CoV-2 vaccines induced a strong humoral response after vaccination. Robust CD4+ and CD8+ memory T cell responses are induced after SARS-CoV-2 infection and play important roles in resolution of the infection, including modulating disease severity in humans and reducing viral load in non-human primates. However, the detection of these specific memory T cells has been poorly studied in the SARS-CoV-2 vaccine development and represent a gap in the understanding of the induced cellular adaptive immune responses which are likely to also play an important role for B cell maturation and development of high affinity antibody against SARS-CoV-2.
In this Special Issue, all papers, reviews, diagnostic methodologies able to shed new light on the mechanisms able to enhance SARS-CoV-2-specific strong and memory immune responses after vaccination are welcome. Additionally, all studies able to clarify the SARS-CoV-2 hybrid immunity which is the interrelationship between immune responses developed after a natural infection and vaccination are included.
Dr. Manon Nayrac
Dr. Alexandra Tauzin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- B cells
- T cells
- immune memory responses
- hybrid immunity